EU Nations Seek New Carbon Market Changes to Prevent High Prices
A group of European Union countries want changes to the region's new carbon market in order to prevent a surge in prices that could trigger a backlash against ambitious climate measures.
Member states including Austria, Belgium, the Czech Republic and Italy are seeking steps such as early auctions of permits and stronger price controls in the EU cap-and-trade carbon program for transport and heating fuels, according to a draft document seen by Bloomberg News. The EU is due to start the Emissions Trading System 2 in 2027, complementing the existing ETS1 system that covers manufacturers, airlines and shipping.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Worldline shares fall over 20% after media investigation
(Reuters) -Worldline shares fell over 20% on Wednesday after an investigation by 21 European media outlets alleged the French digital payments company covered up client fraud to protect revenue. Responding to the reports, Worldline said in a statement that since 2023 it has strengthened merchant risk controls and terminated non-compliant client relationships.
Bloomberg
27 minutes ago
- Bloomberg
Switzerland Seeks Defense Cooperation With EU in New Talks
Switzerland wants to start exploratory talks on a defense partnership with the European Union as worries about a US retreat from the continent prompt a rethink of security policy in the traditionally neutral country. Cooperation should take the form of a 'non-legally-binding declaration of intent,' the government in Bern said in a statement. A partnership of this kind is a prerequisite for any joint procurements in the defense sector, it added.
Yahoo
an hour ago
- Yahoo
AstraZeneca Presents Positive Phase I/II Data for Surovatamig in B-cell ALL at EHA 2025
AstraZeneca (NASDAQ:AZN) is one of the most active stocks to buy according to analysts. On June 16, the preliminary results for AstraZeneca's surovatamig, a next-gen CD19xCD3 bispecific T-cell engager (BiTE), were presented at the 2025 Congress of the European Hematology Association (EHA 2025). The event was held from June 12 to 15 in Milan, Italy. The findings come from the global, multicenter, open-label, and single-arm Phase I/II SYRUS clinical trial (NCT06137118), which is evaluating surovatamig as a monotherapy for patients aged 12 and over with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). B-ALL is an aggressive hematologic malignancy that accounts for 7% to 85% of all acute lymphoblastic leukemia cases and is most commonly diagnosed in young children and adolescents, although its incidence also rises in older adults. A pharmacy worker distributing prescription medicines to patientsreceiving treatment for oncology, cardiovascular, renal, metabolism and respiratory diseases. Surovatamig is designed with Fc-engineering for an extended half-life and optimized CD3 binding, which allows for intermittent dosing and controlled T-cell activation. This could offer a convenient and safer alternative to continuous infusion therapies like Blincyto. Beyond R/R B-ALL, surovatamig is also in Phase III trials as a monotherapy for diffuse large B-cell lymphoma and in combination with Biogen's Rituxan (rituximab) for untreated follicular lymphoma. While surovatamig shows promise, it will need to demonstrate superior performance against established therapies such as Blincyto and Aucatzyl. AstraZeneca (NASDAQ:AZN) is a biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines. While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
